By the FormBlends Editorial Team. Medically reviewed by Dr. Sarah Chen, MD.
Last March, a 46-year-old nurse in Tulsa named Rachel spent three weeks trying to figure out what to ask her doctor. She'd been on Ozempic 1 mg for five months, lost 24 pounds, stalled at 211, and kept seeing TikToks about tirzepatide producing "way more" weight loss. Her insurance wouldn't cover Zepbound. A compounded version cost $399 a month. Brand Wegovy at 2.4 mg was theoretically available but perpetually backordered at her pharmacy. "I just wanted someone to lay the options next to each other in plain language," she told me. "Instead I got fifteen influencer videos and a Reddit thread that contradicted itself three times."
Rachel's confusion is the norm. The GLP-1 category has fractured into multiple branded products, two distinct molecules, and a parallel compounded market, all moving at different speeds through different regulatory and insurance pipelines. This page exists to put the actual data side by side.
It draws on the head-to-head SURPASS-2 trial, indirect comparisons across the SURMOUNT and STEP programs, and the regulatory lines separating brand from compounded products. I won't declare a winner. There isn't one. But the trade-offs are real, they're measurable, and they should drive a conversation with your clinician, not replace it.
For broader context on tirzepatide specifically, see the main Compounded Tirzepatide Complete Guide.
Important: Compounded semaglutide and tirzepatide are not FDA-approved. FormBlends is not a medical practice and does not prescribe medication. Drug selection must be a clinical decision with a licensed provider.
Two Molecules, Five Brand Names, and a Compounded Market
Two molecules dominate the current GLP-1 weight management space.
Semaglutide is a long-acting GLP-1 receptor agonist. You'll see it sold as Ozempic (approved for type 2 diabetes), Wegovy (approved for weight management), and Rybelsus (an oral formulation). Ozempic and Wegovy are once-weekly subcutaneous injections. Novo Nordisk makes all three.
Tirzepatide is a dual GLP-1 and GIP receptor agonist. It's sold as Mounjaro (type 2 diabetes) and Zepbound (weight management), both once-weekly injections from Eli Lilly.
The pharmacological difference that matters: tirzepatide hits two receptors. GIP, or glucose-dependent insulinotropic polypeptide, is a separate incretin hormone. Semaglutide activates only GLP-1. Tirzepatide activates both. Think of it like a stereo signal versus mono. Both carry the music; one carries more of it.
The clinical result is that tirzepatide tends to produce greater weight loss and greater A1C reduction at maximally effective doses. The trade-off? A modestly higher rate of GI side effects, particularly constipation. More on that below.
The Only Real Head-to-Head: SURPASS-2
The SURPASS-2 trial (Frias et al., NEJM 2021) is the single large head-to-head comparison between these two molecules. It enrolled 1,879 adults with type 2 diabetes on metformin and randomized them to tirzepatide 5, 10, or 15 mg or semaglutide 1 mg, all once weekly for 40 weeks.
Mean A1C reductions:
- Semaglutide 1 mg: 1.86 percent
- Tirzepatide 5 mg: 2.01 percent
- Tirzepatide 10 mg: 2.24 percent
- Tirzepatide 15 mg: 2.30 percent
Mean weight reductions:
- Semaglutide 1 mg: 6.2 kg
- Tirzepatide 5 mg: 7.6 kg
- Tirzepatide 10 mg: 9.3 kg
- Tirzepatide 15 mg: 11.2 kg
Here's the catch: SURPASS-2 used semaglutide at 1 mg, which is the diabetes dose. The weight management dose (Wegovy) goes up to 2.4 mg weekly. Nobody has run a head-to-head trial pitting semaglutide 2.4 mg against tirzepatide 15 mg in non-diabetic obesity. That trial would cost hundreds of millions of dollars, and neither manufacturer has any incentive to fund it. So we're left with cross-trial comparisons.
Reading Between Trials: SURMOUNT vs STEP
The STEP-1 trial showed semaglutide 2.4 mg produced 14.9 percent mean weight loss in people with obesity. The SURMOUNT-1 trial showed tirzepatide 15 mg produced 20.9 percent mean weight loss in a broadly similar population.
Not sure which GLP-1 is right for you?
Take a 2-minute assessment and get a personalized recommendation after licensed provider review.
Take the Assessment →Indirect comparison. Different enrollment criteria, different sites, different years. But the general conclusion holds: tirzepatide produces roughly 5 to 6 percentage points more weight loss at maximum doses.
Whether that gap matters for an individual patient depends on where they're starting. A 200-pound person losing 21 percent drops 42 pounds. The same person losing 15 percent drops 30 pounds. Both outcomes are clinically significant by any reasonable standard. The difference is 12 pounds. That's real, but it's not the difference between success and failure for most people.
My honest take: if a patient is responding well to semaglutide and tolerating it, the marginal weight-loss benefit of switching to tirzepatide rarely justifies the cost, the titration restart, and the weeks of renewed nausea. If a patient has plateaued on maximally tolerated semaglutide and has meaningful weight left to lose, the switch conversation is worth having.
Side Effects: Similar Profile, Different Intensity
The GI side effect profiles overlap more than they differ. From SURPASS-2, at the highest tirzepatide dose versus semaglutide 1 mg:
- Nausea: 22.1 percent (tirzepatide 15 mg) vs. 17.9 percent (semaglutide 1 mg)
- Diarrhea: 15.6 percent vs. 11.5 percent
- Constipation: 7.5 percent vs. 4.5 percent
- Vomiting: 9.8 percent vs. 8.3 percent
Tirzepatide runs modestly higher across the board. Consistent with a drug doing more pharmacologically. Discontinuation rates due to adverse events were similar in both arms (under 7 percent), which tells you most people found the side effects tolerable even if unpleasant.
The boring truth about GLP-1 side effects: for most patients they peak during titration, diminish over weeks, and become background noise by month three. For a minority, they don't. That minority needs careful dose management or a switch.
For more detail, see our Tirzepatide Side Effects and Safety Hub.
GI Conditions Complicate the Picture
Patients with pre-existing GI disease face a harder decision. Three conditions come up repeatedly.
Diverticular disease. There's been clinical interest in whether GLP-1s exacerbate diverticulitis. The theoretical mechanism: slowed GI motility increasing intracolonic pressure or stasis. Case reports of diverticulitis flares during GLP-1 therapy do exist. But population-level signals from large databases remain unclear. The evidence just isn't there yet to quantify the risk precisely.
Practical guidance: patients with active diverticulitis should not start a GLP-1. Patients with a history of diverticulitis should loop in their gastroenterologist and consider slower titration with aggressive constipation prevention (fiber, hydration, possibly osmotic laxatives). This is a "proceed with eyes open" situation, not an absolute contraindication.
Gastroparesis. Both semaglutide and tirzepatide slow gastric emptying as part of their mechanism. If you already have delayed gastric emptying, these drugs will almost certainly make it worse. Relative contraindication that warrants serious clinical thought.
IBD (Crohn's and ulcerative colitis). Limited data. Some patients tolerate GLP-1s fine; others report symptom flares. There's no clear pharmacological reason to expect IBD exacerbation, but the additive GI burden on top of baseline symptoms can be meaningful.
Our supporting article on GLP-1s and pre-existing GI conditions covers these scenarios in detail.
Cardiovascular Evidence: Semaglutide Leads (For Now)
This is where semaglutide has a clear advantage, at least today.
The SUSTAIN-6 trial showed semaglutide reduced major adverse cardiovascular events (MACE) by 26 percent in patients with type 2 diabetes and cardiovascular risk. The SELECT trial extended this to non-diabetic patients with cardiovascular disease and overweight or obesity, showing a 20 percent reduction in MACE. That's a big deal. It means semaglutide has proven cardiovascular benefit independent of diabetes status.
Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) is ongoing. Preliminary data suggests comparable benefit, but full results aren't available yet.
If a patient's primary driver is cardiovascular risk reduction, semaglutide has the mature evidence. If the primary driver is weight loss or glycemic control, tirzepatide has stronger efficacy numbers. Sometimes both goals matter, and that's where clinical judgment earns its keep.
What Everything Costs
Brand list prices cluster in the same range:
- Wegovy: approximately $1,349/month
- Ozempic: approximately $968/month (lower because the max dose is lower)
- Mounjaro: approximately $1,069/month
- Zepbound: approximately $1,069/month
Insurance coverage is spotty and indication-dependent. Many plans cover Ozempic for diabetes but won't touch Wegovy for weight management. Similar story with Mounjaro vs. Zepbound.
Compounded prices run significantly lower, with compounded tirzepatide typically 10 to 20 percent more than compounded semaglutide at equivalent therapeutic levels. For full cost analysis, see our Tirzepatide Cost and Access Hub.
Compounded vs. Brand: A Different Kind of Decision
Separate from the "which molecule" question is "which product." This is where things get politically and regulatorily charged.
Brand products (Wegovy, Ozempic, Zepbound, Mounjaro) are FDA-approved, manufactured under FDA cGMP standards, potentially insurance-covered for approved indications, and consistent across batches.
Compounded products (semaglutide and tirzepatide from 503A or 503B pharmacies) are not FDA-approved, compounded under USP and state pharmacy standards, cash-pay only, and variable in quality depending on the pharmacy. Same active molecule, but not therapeutically equivalent in the regulatory sense. The regulatory landscape is actively shifting following FDA shortage resolution updates.
Neither option is universally "right." A patient with good insurance coverage and an approved indication should probably use the brand product. A patient paying cash for an off-label use who can't afford $1,300 a month has a legitimate reason to consider compounding. The decision belongs with the patient and clinician, informed by access, cost, and individual risk tolerance.
Note: Same active ingredient does not mean identical product. Compounded GLP-1s are not FDA-approved and are not therapeutically equivalent to brand products in the regulatory sense.
When Each Molecule Makes More Sense
Semaglutide is the stronger pick when:
- Cardiovascular disease is present and MACE reduction is the primary goal
- The patient had intolerable side effects on tirzepatide
- Cost considerations favor semaglutide (compounded semaglutide is often cheaper than compounded tirzepatide)
- The patient is responding well on a sub-maximal dose with no clinical reason to switch
Tirzepatide is the stronger pick when:
- Maximum weight loss is the primary objective
- Type 2 diabetes management needs maximum A1C reduction
- The patient hasn't reached goal on maximally tolerated semaglutide
- The patient and clinician prefer the dual incretin mechanism
For more on transitioning between the two, see our supporting article on switching from semaglutide to tirzepatide.
Related Reading Across This Cluster
This hub anchors a cluster of supporting articles on GLP-1 drug comparison:
- Semaglutide vs Tirzepatide: Side by Side
- Switching from Semaglutide to Tirzepatide
- Ozempic vs Wegovy vs Compounded Semaglutide
- Mounjaro vs Zepbound vs Compounded Tirzepatide
- GLP-1s and Pre-existing GI Conditions
- GLP-1 Cardiovascular Benefits
- GLP-1s and Cancer Risk
- Oral Semaglutide vs Injectable
- Future GLP-1 Drugs in the Pipeline
- GLP-1 vs Bariatric Surgery
Frequently Asked Questions
1. Which is more effective: semaglutide or tirzepatide?
Tirzepatide produces greater mean weight loss and A1C reduction at maximum doses based on trial data. The clinical magnitude of the difference varies by patient. Both are highly effective.
2. Can GLP-1s cause diverticulitis flares?
Evidence is limited. Case reports exist but population-level signals are not clear. Patients with a history of diverticulitis should discuss the risk with their gastroenterologist and consider slower titration with aggressive constipation prevention.
3. Should I take Ozempic or Wegovy?
Ozempic is approved for type 2 diabetes; Wegovy is approved for weight management. The active ingredient is the same (semaglutide), but the maximum approved dose is higher for Wegovy (2.4 mg vs 1 mg). Your indication and insurance situation typically drive the choice.
4. Is Mounjaro the same as Zepbound?
Yes, the active ingredient is identical (tirzepatide). Mounjaro is the brand name for type 2 diabetes; Zepbound is the brand name for chronic weight management. Both are made by Eli Lilly.
5. Is compounded semaglutide the same as Ozempic?
The active pharmaceutical ingredient is the same molecule. The finished product is not the same. Compounded semaglutide is not FDA-approved and is not therapeutically equivalent in the regulatory sense.
6. What is GIP and why does it matter?
GIP is glucose-dependent insulinotropic polypeptide, a second incretin hormone. Tirzepatide activates GIP receptors in addition to GLP-1 receptors. Semaglutide does not. The dual activation appears to contribute to tirzepatide's stronger weight loss effect.
7. Can I take both semaglutide and tirzepatide?
No. Combining GLP-1 receptor agonists is not safe and is not supported by any clinical data. Switch from one to the other only under clinician supervision.
8. How do I switch from semaglutide to tirzepatide?
Generally, stop semaglutide and start tirzepatide at 2.5 mg one week after the last semaglutide dose. Discuss the specific protocol with your clinician. The supporting article on switching covers timing and dose-equivalent considerations.
9. Which has fewer side effects?
Semaglutide tends to have modestly lower rates of GI side effects in head-to-head trial data, particularly diarrhea and constipation. The difference is measurable but not dramatic.
10. Will newer GLP-1 drugs replace these?
Several next-generation incretin drugs are in trials, including retatrutide (a triple agonist) and CagriSema (semaglutide plus an amylin agonist). Early data suggests greater weight loss than current drugs. Approval timelines extend into 2026 and beyond.
---
Disclaimer: This article is for informational purposes only and is not medical advice. Compounded semaglutide and tirzepatide are not FDA-approved. FormBlends is not a medical practice and does not prescribe medication. Always consult a licensed clinician about drug selection.
Return to the Compounded Tirzepatide Complete Guide.